Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Arctic Bioscience AS ( (DE:9TD) ).
Arctic Bioscience AS will publish an operational update for the fourth quarter of 2025 on Thursday 26 February 2026 at 07:00, followed by a webcast presentation at 10:00 in Norwegian and English. The webcast, which will include a Q&A session, gives investors and other stakeholders an opportunity to engage directly with management and gain insight into the company’s recent operational developments and strategic progress.
More about Arctic Bioscience AS
Arctic Bioscience AS is a biotechnology company that develops and commercializes pharmaceutical products and dietary supplements derived from bioactive marine raw materials. Its pipeline includes HRO350, an oral drug candidate for mild-to-moderate psoriasis, while its ROMEGA-branded marine-based dietary supplements are sold globally both as bulk ingredients and finished products.
YTD Price Performance: -5.18%
Average Trading Volume: 17,598
Current Market Cap: NOK90.3M
For an in-depth examination of 9TD stock, go to TipRanks’ Overview page.